Patents by Inventor Ditte Riber

Ditte Riber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS
    Publication number: 20190135886
    Abstract: The present invention relates to truncated GIP analogues which comprise one or more substitutions as compared to wild-type GIP and which may have the property of an altered, preferably increased GLP-1 activity, e.g. as assessed in in vitro efficacy assays. The invention provides GIP-GLP-1 dual agonist compounds and associated methods.
    Type: Application
    Filed: September 5, 2018
    Publication date: May 9, 2019
    Inventors: Rasmus JUST, Ditte RIBER, Anne Pernille Tofteng SHELTON, Torben ØSTERLUND, Kate HANSEN, Lene JESSEN
  • Glucagon-like-peptide-2 (GLP-2) analogues
    Patent number: 10253080
    Abstract: GLP-2 analogs are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogs are particularly useful for the prophylaxis treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: April 9, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Kirsten Lindegaard Bovbjerg, Ditte Riber, Wayne Shaun Russell
  • Glucagon analogues
    Patent number: 10253081
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 9, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas, Wolfgang Rist
  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20190076506
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: May 22, 2018
    Publication date: March 14, 2019
    Inventors: Ditte RIBER, Eddi MEIER, Jens Rosengren DAUGAARD, Marie SKOVGAARD, Jakob Lind TOLBORG, Gita KAMPEN, Camilla Ærteberg BÆK
  • GLUCAGON ANALOGUES
    Publication number: 20190055296
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: May 18, 2018
    Publication date: February 21, 2019
    Inventors: Jakob Lind TOLBORG, Keld FOSGERAU, Pia NØRREGAARD, Rasmus JUST, Ditte RIBER, Dieter Wolfgang HAMPRECHT, Robert AUGUSTIN, Leo THOMAS, Wolfgang RIST
  • GLUCAGON ANALOGUES
    Publication number: 20180355010
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: May 4, 2018
    Publication date: December 13, 2018
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT
  • Glucagon-GLP-1-GIP triple agonist compounds
    Patent number: 10131702
    Abstract: The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: November 20, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Ditte Riber, Anne Pernille Tofteng Shelton, Torben Østerlund, Kate Hansen, Lene Jessen
  • GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES
    Publication number: 20180298077
    Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogues are particularly useful for the prophylaxis treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.
    Type: Application
    Filed: April 11, 2018
    Publication date: October 18, 2018
    Inventors: Rasmus JUST, Kirsten Lindegaard BOVBJERG, Ditte RIBER, Wayne Shaun RUSSELL
  • GIP-GLP-1 dual agonist compounds and methods
    Patent number: 10100097
    Abstract: The present invention relates to truncated GIP analogs which comprise one or more substitutions as compared to wild-type GIP and which may have the property of an altered, preferably increased GLP-1 activity, e.g. as assessed in in vitro efficacy assays. The invention provides GIP-GLP-1 dual agonist compounds and associated methods.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: October 16, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Ditte Riber, Anne Pernille Tofteng Shelton, Torben Østerlund, Kate Hansen, Lene Jessen
  • Acylated glucagon analogues
    Patent number: 10004786
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: June 26, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Eddi Meier, Jens Rosengren Daugaard, Marie Skovgaard, Jakob Lind Tolborg, Gita Kampen, Camilla Ærteberg Bæk
  • Glucagon analogues
    Patent number: 9988429
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: June 5, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht
  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20180141990
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: December 22, 2017
    Publication date: May 24, 2018
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Wolfgang RIST
  • Glucagon analogues
    Patent number: 9975939
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: May 22, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Jakob Lind Tolborg, Keld Fosgerau, Pia Nørregaard, Rasmus Just, Ditte Riber, Dieter Wolfgang Hamprecht, Robert Augustin, Leo Thomas, Wolfgang Rist
  • Glucagon-like-peptide-2 (GLP-2) analogues
    Patent number: 9969787
    Abstract: GLP-2 analogs are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogs are particularly useful for the prophylaxis treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: May 15, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Rasmus Just, Kirsten Lindegaard Bovbjerg, Ditte Riber, Wayne Shaun Russell
  • ACYLATED GLUCAGON ANALOGUE
    Publication number: 20180094038
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: April 15, 2016
    Publication date: April 5, 2018
    Inventors: Ditte RIBER, Jakob Lind TOLBORG, Dieter Wolfgang HAMPRECHT, Leo THOMAS
  • Acylated glucagon analogues
    Patent number: 9896495
    Abstract: The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: February 20, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Jakob Lind Tolborg, Dieter Wolfgang Hamprecht, Wolfgang Rist
  • GHRELIN ANALOGUES
    Publication number: 20180009849
    Abstract: The present invention relates, inter alia, to ghrelin analogues and their medical use, for example in the treatment of cachexia, chronic obstructive pulmonary disease, gastrointestinal disorders (e.g., gastroparesis and/or inflammatory disorders such as colitis, gut barrier dysfunction, and ischemia reperfusion injury), loss of body weight, and decreased appetite.
    Type: Application
    Filed: April 12, 2017
    Publication date: January 11, 2018
    Inventors: Simon Birksø LARSEN, Ditte RIBER
  • Ghrelin analogues
    Patent number: 9657062
    Abstract: The present invention relates, inter alia, to ghrelin analogs and their medical use, for example in the treatment of cachexia, chronic obstructive pulmonary disease, gastrointestinal disorders (e.g., gastroparesis and/or inflammatory disorders such as colitis, gut barrier dysfunction, and ischemia reperfusion injury), loss of body weight, and decreased appetite.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: May 23, 2017
    Assignee: Zealand Pharma A/S
    Inventors: Simon Birksø Larsen, Ditte Riber
  • GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES
    Publication number: 20160355563
    Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogues are particularly useful for the prophylaxis treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.
    Type: Application
    Filed: August 16, 2016
    Publication date: December 8, 2016
    Inventors: Rasmus JUST, Kirsten Lindegaard BOVBJERG, Ditte RIBER, Wayne Shaun RUSSELL
  • GLUCAGON ANALOGUES
    Publication number: 20160347813
    Abstract: The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain, and the treatment of obesity or excess body weight and associated conditions. The compounds may also be used to improve glycemic control and/or for the treatment of diabetes. The compounds may mediate their effect, inter alia, by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: August 17, 2016
    Publication date: December 1, 2016
    Inventors: Dieter Wolfgang HAMPRECHT, Jakob Lind TOLBORG, Ditte RIBER